ImpediMed Future Growth

Future criteria checks 2/6

ImpediMed is forecast to grow earnings and revenue by 49.7% and 39.8% per annum respectively. EPS is expected to grow by 55.3% per annum. Return on equity is forecast to be -11.9% in 3 years.

Key information

49.7%

Earnings growth rate

55.3%

EPS growth rate

Medical Equipment earnings growth17.2%
Revenue growth rate39.8%
Future return on equity-11.9%
Analyst coverage

Low

Last updated01 May 2024

Recent future growth updates

Recent updates

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Mar 05
ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Nov 23
Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

Jul 11
Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Mar 27
We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10
We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01
A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12
Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08
ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Nov 25
How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Earnings and Revenue Growth Forecasts

ASX:IPD - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202632-2-121
6/30/202519-14-17-132
6/30/202411-21-23-182
12/31/202310-19-18-13N/A
9/30/202311-20-21-15N/A
6/30/202311-21-24-18N/A
3/31/202311-21-25-20N/A
12/31/202211-22-27-22N/A
9/30/202211-21-24-19N/A
6/30/202211-20-21-16N/A
3/31/202210-20-19-14N/A
12/31/202110-19-17-13N/A
9/30/20219-20-16-13N/A
6/30/20218-21-16-13N/A
3/31/20217-20-17-15N/A
12/31/20206-19-18-16N/A
9/30/20206-20-20-18N/A
6/30/20206-21-21-19N/A
12/31/20195-25-22-20N/A
9/30/20195-24-22-20N/A
6/30/20194-24-22-20N/A
12/31/20184-25-23-21N/A
9/30/20183-26-24-22N/A
6/30/20183-27-25-23N/A
3/31/20184-28N/AN/AN/A
12/31/20174-28-26-26N/A
9/30/20175-28N/A-26N/A
6/30/20176-28N/A-26N/A
3/31/20176-28N/A-25N/A
12/31/20166-29N/A-25N/A
9/30/20166-27N/A-24N/A
6/30/20166-26N/A-22N/A
3/31/20166-23N/A-19N/A
12/31/20155-20N/A-16N/A
9/30/20155-17N/A-13N/A
6/30/20155-15N/A-11N/A
3/31/20154-13N/A-9N/A
12/31/20144-10N/A-8N/A
9/30/20144-9N/A-7N/A
6/30/20144-8N/A-7N/A
3/31/20143-7N/A-6N/A
12/31/20133-7N/A-6N/A
9/30/20133-8N/A-7N/A
6/30/20133-8N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IPD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IPD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IPD's revenue (39.8% per year) is forecast to grow faster than the Australian market (5.4% per year).

High Growth Revenue: IPD's revenue (39.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IPD is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.